Skip to main content

Table 1 BMI and plasma parameters of type 2 diabetic patients before and after rosiglitazone treatment and of non-diabetic controls.

From: Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus

  Diabetic patients (n = 11) Controls (n = 10)
  Before treatment After treatment  
BMI (kg/m2) 30 ± 1.0 31 ± 1.0 31 ± 1.3
Glucose (mmol/L) 9.2 ± 0.5a 8.1 ± 0.5b,c 5.8 ± 0.1
Insulin (mU/L) 24.1± 3.1a 17.2 ± 1.7b,c 12.3 ± 0.9
GIR (μmol/kg/min) 12.8± 1.3a 20.6 ± 1.7b 24.6 ± 2.4
Total cholesterol (mmol/L) 5.4 ± 0.3 5.7 ± 0.4 5.2 ± 0.3
LDL cholesterol (mmol/L) 3.5 ± 0.2 3.8 ± 0.4 3.4 ± 0.3
HDL cholesterol (mmol/L) 0.93 ± 0.1 1.10± 0.1b 1.14 ± 0.1
TCH/HDL ratio 6.9 ± 1.1 5.5 ± 1.0 5.5 ± 1.1
Triglycerides (mmol/L) 2.0 ± 0.3 1.5 ± 0.2b 1.5 ± 0.4
FFA (mmol/L) 509 ± 47 400 ± 37b 513 ± 45.6
  1. a Significantly different (P < 0.05) between diabetic patients and non-diabetic controls
  2. b Significant effect (P < 0.05) of rosiglitazone treatment in diabetic patients
  3. c Significantly different (P < 0.05) between diabetic patients after rosiglitazone treatment and non-diabetic controls